The effect of CKD fineness on the consistency and setting time ...
Diabetes and CKD: is it all about managing glucose - PACE ...
-
Upload
khangminh22 -
Category
Documents
-
view
1 -
download
0
Transcript of Diabetes and CKD: is it all about managing glucose - PACE ...
Diabetes and CKD: is it all about managing glucose
Melanie J Davies CBE FMedSci Professor of Diabetes Medicine
Agenda
• Metabolic-cardio-renal cross-talk and role of GLP-1RA
• Glucose lowering in T2D and CKD
• Summary
Patients with T2D are at increased risk of complications such as CV disease, HF and CKD
*Patients with T2D aged <55 years CKD, chronic kidney disease; CV, cardiovascular; DKD, diabetic kidney disease; ESKD, end-stage kidney disease; HF, heart failure; HHF, hospitalisation for heart failure; T2D, type 2 diabetes
1. Younossi ZM et al. J Hepatology 2019;71:793; 2. Masmiquel L et al. Cardiovasc Diabetol 2016;15:29; 3. International Diabetes Foundation. Diabetes Atlas 8th Edition. http://www.diabetesatlas.org (accessed Jan 2020); 4. Rosengren A et al. Diabetologia 2018;61:2300; 5. Mozaffarian D et al. Circulation 2016;133:e38; 6. MacDonald MR et al. Eur Heart J 2008;29:1377; 7. Thomas M et al. Nat Rev Nephrol 2016;12:73; 8. Toth-Manikowski S & Atta MG. J Diabetes Res 2015;2015:697010; 9. World Health Organisation. https://www.who.int/bulletin/volumes/96/6/17-206441/en/ (accessed Jan 2020); 10. Ather S et al. J Am Coll Cardiol 2012;59:998.
T2D
CKD CV disease/ HF
• CKD affects ∽50% of patients with T2D7
• Diabetes is the most common reason for progression to ESKD, accounting for 30-50% of ESKD8
• Approximately one in three patients with T2D has CV disease3
• 2- to 5-fold increased risk of HF in patients with T2D*4
• 60–80% greater probability of CV death and all-cause mortality in those with T2D and established HF5,6
• 17–21% of patients with CKD also have HF9
• Presence of CKD in patients with HF increases risk of mortality by ~25–30%10
• ~55% with T2D have NAFLD1
• Over half of patients with T2D are reported to be obese2
Regulation of energy metabolism is essential for
healthy function, especially in the heart and kidneys1,2
The heart is the most metabolically demanding organ, susceptible to changes
in volume or metabolism1
The kidneys play a key role in glucose and volume homeostasis3,4
1. Lopashuk GD & Ussher JR. Circ Res 2016;119:1173; 2. de Boer IH & Utzschneider KM. Nephrol Dial Transplant 2017;32:588; 3. García-Donaire JA & Ruilope LM. Int J Nephrol 2011;2011:975782; 4. Alsahli M & Gerich JE Diabetes Res Clin Pract 2017;133:1
The cardiovascular, renal and metabolic systems are interrelated
• Diseases of the CRM system share many of the same risk factors3
• Dysfunction in one system leads to progression of interrelated diseases4 such as T2D, CV disease, HF, and CKD, which in turn lead to an increased risk of CV death5
CKD, chronic kidney disease; CRM, cardio-renal-metabolic; CV, cardiovascular; HF, heart failure; T2D, type 2 diabetes CRM, cardio-renal-metabolic; CV, cardiovascular; HF, heart failure; T2D, type 2 diabetes 1. García-Donaire JA & Ruilope LM. Int J Nephrol 2011;2011:975782; 2. Thomas G et al. Clin J Am Soc Nephrol 2011;6:2364; 3. Sarafidis PA et al. J Cardiometab Syndr 2006:58; 4. Ronco C et al. Contrib Nephrol 2010;165:54; 5. Leon BM and Maddox TM. World J Diabetes 2015;6:1246
Dysfunction of the heart, kidneys or metabolism contributes to the dysfunction of the others1,2
Energy metabolism
Cardiovascular
Renal
Fluid retention2
Albuminuria1
Renal failure1
1. Connell AW & Sowers JR. J Am Soc Hypertens 2014;8:604; 2. Ronco C et al. J Am Coll Cardiol 2008;52:1527
Metabolic dysfunction adds to cardio–renal disease progression and outcomes1,2
Glucotoxicity Lipotoxicity1
↑ Insulin resistance1
Altered hormonal milieu1
↑ Adipokines1
Energy metabolism
Cardiac failure2
Vascular dysfunction1
Atherosclerosis2
FFA, free fatty acids 1. Connell AW & Sowers JR. J Am Soc Hypertens 2014;8:604; 2. Ronco C et al. J Am Coll Cardiol 2008;52:1527; 4. Lopashuk GD & Ussher JR. Circ Res 2016;119:1173
Cardiac abnormalities affect renal/metabolic disease progression and outcomes1,2
Cardiac dysfunction adds to the renal/metabolic burden1,2
Cardiovascular Hypoperfusion2 Volume overload2
↑ Arterial resistance2
Neurohormonal activation1,2
∆ Substrate utilisation3
Autonomic dysfunction1,2
↑ Insulin resistance1
↑ FFA and lipotoxicity4
Hypertension1,2
Albuminuria1,2 Renal failure1
Ventricular hypertrophy2
Cardiac failure2 Vascular dysfunction1,2
Atherosclerosis2
↑ Insulin resistance1
↑ Hypoglycaemia
RAAS, renin–angiotensin–aldosterone system; SNS, sympathetic nervous system 1. Connell AW & Sowers JR. J Am Soc Hypertens 2014;8:604; 2. Cabundugama PK et al. Med Clin North Am 2017;101:129
Renal abnormalities affect cardiac and metabolic disease progression and outcomes1,2
Renal dysfunction adds to cardiac and metabolic burden
Renal1,2
Hypertension Fluid retention
Oxidative stress Arterial calcification
Activation of the RAAS & SNS
GLP-1 in the treatment of diabetes
Lowering of blood glucose Increased insulin, lowered glucagon, gastric emptying
Lowering of body weight Lowered food intake, increased satiety, reduced hunger
Cardiovascular effects Reduced blood pressure, lipids, inflammation
GLP-1, the conductor of the diabetes orchestra…
…that works on many important organs
Drucker D. Cell Metab 2016;24:15–30
GLP-1 RA, glucagon-like peptide-1 receptor agonist Adapted from Drucker D. Cell Metab 2018;27:740; Rizzo M et al. Biochim Biophys Acta Mol Basis Dis 2018;1864:2814
Effects of GLP-1 receptor agonists on the cardio-renal-metabolic systems
Intermediate Effects
Natriuresis
Diuresis
Downstream observed effects
GLP-1 RA
Coagulation Inflammation
CV events
Blood pressure
Body weight
HbA1c Postprandial lipids
Insulin secretion
Glucagon suppression
LV function
Agenda
• Metabolic-cardio-renal cross-talk and role of GLP-1RA
• Glucose lowering in T2D and CKD
• Summary
Turnbull FM et al. Diabetologia 2009;52:2288
Meta-analysis of the ACCORD, ADVANCE, UKPDS and VADT studies
Limited CV benefits have been observed with intensive glycaemic control in patients with T2D
Objective: to generate precise estimates of the effects of glucose-lowering
therapy on major CV events Major CV
events
Limited benefit HR 0.91 (0.84, 0.99)
All-cause mortality
No effect HR 1.04 (0.90, 1.20)
Patients with T2D (N=27,049) allocated to ‘More intensive’ or ‘Less intensive’ glycaemic
control
Composite end-point: time to incident CVD, number of CV events, mortality and CVD rates CV, cardiovascular; CVD, cardiovascular disease; T2D, type 2 diabetes Gaede P et al. Diabetologia 2016;59:2298
Steno-2: Intensive multifactorial control of CV risk factors reduces CV risk in patients with T2D and microalbuminuria
Multifactorial control of CV risk factors reduced CV risk in T2D patients
Conventional (51 events)
Intensive (35 events)
Unadjusted HR 0.55 (95% CI 0.39, 0.77); p=<0.001
*Existing ASCVD or 10-year ASCVD risk ≥15%; †10-year ASCVD risk <15%; ‡Empagliflozin, canagliflozin, and dapagliflozin reduce CV events in patients with DM and CVD or are at very high/high CV risk; §Liraglutide, semaglutide and dulaglutide reduce CV events in patients with DM and CVD, or who are at very high/high CV risk ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; T2D, Type 2 Diabetes; RAAS, renin-angiotensin-aldosterone system 1. American Diabetes Association. Diabetes Care 2020;43:S1; 2. Cosentino F et al. Eur Heart J 2020;7:255
Management approaches focus on reducing the risk of CV death in patients with T2D1,2
Multifactorial management established as standard of care for patients with T2D1,2
Target Treatment
Blood pressure-lowering
For individuals with T2D and hypertension, a blood pressure target of: • <130/80 mmHg if at higher CV risk*1
• <140/90 mmHg if at lower risk for CV disease†1
• RAAS blocker, and a calcium channel blocker or diuretic
• Dual therapy is recommended as first-line treatment
LDL cholesterol-lowering
• <1.8 mmol/l (<70 mg/dl) with LDL-C reduction of ≥50% if at high CV risk
• <2.6 mmol/l (<100 mg/dl) if at moderate CV risk • Statins, ezetimibe or a PCSK9 inhibitor
Glucose control Targets are individualised – generally HbA1c <7% • SGLT2 inhibitors‡, GLP-1 RA§, DPP-4
inhibitors, metformin, sulfonylureas, thiazolidinediones, insulin
Individualised diet and lifestyle Weight loss and smoking cessation
• Diet • Physical activity • Behavioural therapy
Not intended for direct comparison; comparison of trials should be interpreted with caution due to differences in study design, populations and methodology *Empagliflozin only; †Liraglutide only; ‡Most commonly doubling serum creatinine, ESKD, renal death ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; GLP1-RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalisation for heart failure; MACE, major adverse cardiovascular events; SGLT2i, sodium-glucose co-transporter-2 inhibitor
Effects of drug classes on CV, HF and kidney outcomes
SGLT2i GLP1-RA ACEi ARB Statins
MACE
CV death * †
HHF
Hard renal endpoints
Albuminuria
All-cause mortality
Decision cycle for patient-centred glycaemic management in Type 2 diabetes
Davies MJ et al. Diabetes Care 2018. Sep; dci180033. https://doi.org/10.2337/dci18-0033; Davies MJ et al. Diabetologia 2018. https://doi.org/10.1007/s00125-018-4729-5
Presence of ASCVD, CKD or HF is a compelling indication
Buse et al. Diabetes Care. 2019 Dec 19. https://doi.org/10.2337/dci19-0066. Davies MJ et al. Diabetes Care 2018. Sep; dci180033. https://doi.org/10.2337/dci18-0033; Davies MJ et al. Diabetologia 2018. https://doi.org/10.1007/s00125-018-4729-5
Step 1: Assess cardiovascular disease
“In appropriate high-risk individuals with established T2D, the decision to treat with a GLP-1 RA or SGLT2 inhibitor to reduce MACE, HHF, CV death or CKD progression should be considered independently of baseline HbA1c or individualised HbA1c target”1
ASCVD, atherosclerotic cardiovascular disease; HHF, hospitalisation for heart failure 1. Buse JB et al. Diabetes Care 2020;43:487; 2. American Diabetes Association. Diabetes Care 2020;43:S1; 3. Davies MJ et al. Diabetes Care 2018;41:2669
ADA–EASD 2019 Consensus Report update
ADA–EASD consensus for Management of Hyperglycaemia
These recommendations have been also incorporated into the ADA Standards of Medical Care in Diabetes 20202 and should be considered in conjunction with the ADA–EASD 2018 consensus report3
GLP-1 RAs in T2D: HbA1c
BID, twice daily; BW, body weight; GLP-1 RA, glucagon-like peptide-1 receptor agonist; OD, once daily; QW, once a week; T2D, type 2 diabetes. *Liraglutide 0.6–1.8 mg, lixisenatide 10–20 µg; †liraglutide 1.2 mg. 1. Madsbad S. Diabetes Obes and Metab 2016;18(4):317–32; 2. Trujillo M, et al. Ther Adv Endocrinol Metab 2015;6(1)19–28; 3. Nauck M, et al. Diabetes Care 2016:39(9):1501–9; 4. Ahmann AJ et al. Diabetes Care 2018;41:258–66; 5. Pratley RE et al. Lancet Diabetes Endocrinol 2018;6:275–86; 6. Capehorn M et al. Diabetes UK Annual Conference 2019;P439.
-1.9
-1.6
-1.4
-0.8
-1.5 -1.4
-1.1
-1.5
-1.8
-0.5
-1
-1.5
-1.8 -1.7
-1.5
-0.9
-1.1 -1 -1
-1.4
-0.8
-1.3 -1.2
-0.3
-0.8 -0.9
-1.4
-1
-2.5
-2
-1.5
-1
-0.5
0DURATION-1 DURATION-5 Ji et al GetGoal-X AWARD-1 AWARD-6 LEAD-6 DURATION-6 Nauck et al Kapitza et al HARMONY-7 SUSTAIN 3 SUSTAIN 7 SUSTAIN 10
8.3 8.3 Baseline
HbA1c
Cha
nge
from
bas
elin
e in
HbA
1c (%
)
8.5 8.4 8.7 8.7 8.0 8.0 8.1 8.1 8.1 8.1 8.2 8.1 8.4 8.5 8.4 8.4 7.4 7.2 8.2 8.2 8.4 8.3 8.2 8.2 8.2 8.3
Exenatide 10 µg BID Exenatide 2 mg QW
Liraglutide 1.8 mg OD Lixisenatide 20 µg OD
Albiglutide 50 mg QW Dulaglutide 1.5 mg QW
Semaglutide 1.0 mg QW
Choosing glucose-lowering medication if compelling need to minimise weight gain or promote weight loss
1. Semaglutide > liraglutide > dulaglutide > exenatide > lixisenatide 2. Be aware that SGLT2i vary by region and individual agent with regard to indicated level of eGFR for initiation and continued use 3. Choose later generation SU with lower risk of hypoglycaemia 4. Low dose may be better tolerated though less well studied for CVD effects
Davies MJ et al. Diabetes Care 2018. Sep; dci180033. https://doi.org/10.2337/dci18-0033 Davies MJ et al. Diabetologia 2018. https://doi.org/10.1007/s00125-018-4729-5
Semaglutide Liraglutide Exenatide Lixisenatide Dulaglutide
GLP-1 RAs in T2D: weight
BID, twice daily; BW, body weight; GLP-1 RA, glucagon-like peptide-1 receptor agonist; OD, once daily; QW, once a week; T2D, type 2 diabetes. *Liraglutide 0.6–1.8 mg, lixisenatide 10–20 µg; †liraglutide 1.2 mg. 1. Madsbad S. Diabetes Obes and Metab 2016;18(4):317–32; 2. Trujillo M, et al. Ther Adv Endocrinol Metab 2015;6(1)19–28; 3. Nauck M, et al. Diabetes Care 2016:39(9):1501–9; 4. Ahmann AJ et al. Diabetes Care 2018;41:258–66; 5. Pratley RE et al. Lancet Diabetes Endocrinol 2018;6:275–86; 6. Capehorn M et al. Diabetes UK Annual Conference 2019;P439.
-3.7
-2.3
-1.6
-3
-1.3
-3.6
-3.2
-3.6
-4.3
-2.4 -2.2
-5.6
-6.5
-5.8
-3.6
-1.4
-2.5
-4
-1.1
-2.9 -2.9 -2.7
-3.7
-1.6
-0.6
-1.9
-3
-1.9
-7
-6
-5
-4
-3
-2
-1
0DURATION-1 DURATION-5 Ji et al GetGoal-X AWARD-1 AWARD-6 LEAD-6 DURATION-6 Nauck et al Kapitza et al HARMONY-7 SUSTAIN 3 SUSTAIN 7 SUSTAIN 10
102 102 Baseline
BW
Cha
nge
from
bas
elin
e in
BW
(kg)
97 94 70 70 94 96 96 97 94 94 93 93 91 91 102 101 93 91 93 92 96 95 96 93 97 97
Exenatide 10 µg BID Exenatide 2 mg QW
Liraglutide 1.8 mg OD Lixisenatide 20 µg OD
Albiglutide 50 mg QW Dulaglutide 1.5 mg QW
Semaglutide 1.0 mg QW
Possible cardiorenal mechanistic interactions between SGLT2 inhibitors and GLP-1RAs
SGLT2 inhibition GLP1-RA
Anticipated impact of Combination SGLT2 inhibitor-GLP1 RA
therapy Renal parameters Renal hemodynamics ↓ Glomerular hypertension ↔ ↓ Glomerular hypertension
Albuminuria ↓30%–50% ↓20%–30% ↓↓
Inflammation ↓MCP-1, IL-6, NF-kB, ROS ↓ Inflammation, ROS ↓↓
Natriuresis ↑Proximal natriuresis (FENa+) ↑Proximal natriuresis (FENa+) ↑↑
Blood pressure ↓4–6 mm Hg ↔/↓ ↓↓
Cardiovascular events
Ischemic events ↔/↓ ↓ ↓/↓↓
Heart failure ↓/↓ ↔ ↓/↓↓
Metabolic parameters
HbA1c ↓ ↓ ↓↓
Weight ↓ ↓ ↓↓
Heerspink, Kidney International. 2018
Agenda
• Metabolic-cardio-renal cross-talk and role of GLP-1RA
• Glucose lowering in T2D and CKD
• Summary
Summary
• Type 2 diabetes is associated with increased cardio-renal morbidity and mortality
• CVOTs with glucose lowering agents reveal between and within class difference in cardio-renal protection
• The ADA/EASD consensus suggests the new evidence should fundamentally change how we manage patients with T2DM and CKD